about
Intracellular detection and evolution of site-specific proteases using a genetic selection systemEGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuGenetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignanciesEfficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine modelProteases as therapeutics.Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.Cell death-independent functions of granzymes: hit viruses where it hurts.Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein.Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.Granzyme B-truncated VEGF fusion protein represses angiogenesis and tumor growth of OSCC.Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.Human Granzyme B Based Targeted Cytolytic Fusion Proteins.Design of human granzyme B variants resistant to serpin B9
P2860
Q28257999-0B218A15-F518-434E-8E4A-0D95DBBEAD07Q31115054-3E3617D1-D747-4CB6-944B-6C9F3CB8A6A9Q33720126-AF4E383A-3882-41C3-99F1-C1F7D690DD5FQ34773994-656C6A36-B37B-42E1-95C4-A74311049452Q35541200-6A2BCE6C-3A54-4E83-BEEB-2DE443130A52Q36662017-779EF5B8-D17E-4963-B41F-DE9A4ED3B49EQ36736543-6A03F18C-DBD6-4664-A7F7-DC5B03D4E742Q37853216-662CA052-F432-42E8-A8BF-207F5891209BQ37859775-A4E9C950-81E6-4FEF-8535-C5942762A252Q37895629-4C5DD0A3-8DC6-4AC6-8C99-C91ECD7F788AQ38262399-F15F0BD8-AAEF-46E9-B3EE-032E721EDAACQ42004462-F58FC532-7DA3-467A-8CC1-DB9FA2429290Q43743967-BBCB1E7C-36C8-4E34-B411-747B3D4AD9A7Q50886676-5E2FD029-96DF-4CF7-B9CE-C96F144B770DQ50985152-B1D93EA6-82F6-401D-A323-55819A3EE73BQ51707071-20DD5FD5-BECF-488F-AD4E-10700F6F85F6Q53621236-91087BCA-9242-4805-8B27-22155D055814Q55647066-DE5E58BA-3578-4B24-9327-E4EDDC0CCCD0Q57278499-D4B005FD-7890-4153-A7FE-88C8BAF4981E
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Delivery and therapeutic potential of human granzyme B.
@ast
Delivery and therapeutic potential of human granzyme B.
@en
Delivery and therapeutic potential of human granzyme B.
@nl
type
label
Delivery and therapeutic potential of human granzyme B.
@ast
Delivery and therapeutic potential of human granzyme B.
@en
Delivery and therapeutic potential of human granzyme B.
@nl
prefLabel
Delivery and therapeutic potential of human granzyme B.
@ast
Delivery and therapeutic potential of human granzyme B.
@en
Delivery and therapeutic potential of human granzyme B.
@nl
P2860
P1476
Delivery and therapeutic potential of human granzyme B.
@en
P2093
Dieter E Jenne
Florian C Kurschus
P2860
P304
P356
10.1111/J.0105-2896.2010.00894.X
P577
2010-05-01T00:00:00Z